Verdane acquires stake in Qbtech / ADHD diagnostic software
Stockholm | Houston — Qbtech, the software provider of the objective ADHD tests QbTest and QbCheck, today announces an investment from growth-focused equity investor Verdane. Qbtech is the market leader in objective measurement of ADHD symptoms and is transforming ADHD treatment for individuals and society at large. In collaboration with healthcare and education professionals in the U.S. and Europe, Qbtech shortens time to diagnosis and enables optimization of treatment for children and adults with ADHD. Verdane’s investment will help Qbtech further accelerate growth through new technologies, new customer segments and by significantly expanding in existing markets.
Qbtech’s mission is to improve the lives of people with ADHD and to help more patients access quality treatment. To achieve this, Qbtech will support patients and promote new models of care that increase access to care while improving clinical and medical outcomes. Qbtech’s current products improve the skills of professionals through objective data and training, helping to address the dual challenges of workforce shortages and the dramatic increase in demand for ADHD care following the COVID pandemic. Future products will build on this and put patients at the center of their treatment.
“Verdane is an experienced investor in healthcare software, and we look forward to working with Qbtech at this pivotal moment in their growth journey,” said Henrik Aspén of Verdane (photo, copyright Verdane). “Qbtech offers unique technology that is driving the standard for clinical validation and advancing new technologies at a rapid pace. Our team is impressed with their breakthrough, innovative technologies that improve care, reduce healthcare costs and provide an amazing experience for patients and their families.”
The investment in Qbtech is made from Verdane’s Idun Fund, which is classified as “Article 9” under the EU Financial Disclosure Regulation. Idun makes investments focused on driving impact in three areas: Energy Transition, Sustainable Consumption, and Resilient Communities. Previous investments include Auntie, a digital provider of workplace wellness services; Spond, a digital provider of grassroots sports and physical health; and EVA Global, a managed services provider supporting the global shift to electric vehicles. To date, Verdane has invested in over 30 sustainable society companies.
“We are pleased that Verdane is confident in our track record and mission to transform ADHD care. We have always strived to import the best aspects of healthcare technology into medical technology, and Verdane’s expertise in technology and software-enabled businesses will be of great value to us,” said Carl Reuterskiold, CEO of Qbtech.
Founded in 2002, Qbtech is a privately held Swedish company that has developed leading solutions and products to improve the identification, diagnosis, treatment and follow-up of patients with ADHD. Qbtech operates in 13 countries and has offices in Stockholm, Houston and London. Qbtech is an award-winning company recognized for its innovation, and was recently awarded the 2022 HSJ Partnership Award for “Best Partnership with the NHS in Mental Health. www.qbtech.com
Verdane is a growth capital investment specialist firm that partners with technology-based and sustainable European companies to help them reach the next level of international growth. Verdane can invest as a minority or majority investor, either in individual companies or in portfolios of companies, and focuses on three core themes: the digital consumer, software everywhere and sustainable society. The Verdane funds have a total volume of over 4 billion euros and have made over 140 investments in fast-growing companies since 2003. Verdane’s team consists of more than 100 investment and operational professionals based in Berlin, Copenhagen, Helsinki, London, Oslo and Stockholm and aims to be the preferred growth partner for technology-enabled and sustainable companies in Europe.